Medications

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease or obesity.

Most people have missed a dose of prescription medication at some point. But if you are taking a glucagon-like peptide-1 drug—better known as GLP-1—for weight loss, the protocol for getting back on track may be different from missing a dose of antibiotics.

The University of Virginia’s Dr. Anita Clayton has been a primary investigator for nearly every antidepressant approved in the United States since 1990.

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased risk of thyroid cancer.

A new tablet combining albendazole and ivermectin is safe and more effective than albendazole alone in treating Trichuris trichiura and other soil-transmitted helminths (STH), according to a clinical trial conducted by the STOP consortium and led by the Barcelona Institute of Global Health (ISGlobal).

Some maternal medications are associated with lower levels of protein and fat in breastmilk, according to a study published online Jan. 7 in JAMA Network Open.

A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found those insured through Medicare Advantage received less expensive cancer drugs compared to others on Traditional Medicare.

Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their own pharmacies. However, these pharmacies appear less used in Medicare than in other market segments. These PBMs are part of integrated health care conglomerates that own insurance companies and pharmacies, which may create conflicts of interest.

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical Cancer Research.

University of Liverpool researchers have contributed to the largest study to date on sodium valproate use. This significant report shows decreased use in women of childbearing age and during pregnancy, as well as young men, due to safety concerns.